Navigation Links
AlphaVax Announces Nomination for 2012 Vaccine Industry Excellence Award
Date:3/20/2012

RESEARCH TRIANGLE PARK, N.C., March 20, 2012 /PRNewswire/ -- AlphaVax, Inc. ("AVX") is pleased to report that it has been selected as a corporate nominee for the 2012 Vaccine Industry Excellence Award as the Best Early-Stage Vaccine Biotech Company. The award will be announced during the World Vaccine Congress meeting in Washington, DC in April.

AVX is pleased to be both included in the list of finalists as deemed by the panel of judges as well as being recognized as a leader in the field. The Company's proprietary replicon technology has been tested in several clinical trials involving approximately 400 patients. In concert with the Duke University Medical Center in Durham, NC, AVX is awaiting the initiation of a Phase I trial in HER2+ breast cancer.

About AlphaVax
Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease.

AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System
2. GeoVax Announces Private Placement of $2.2 Million
3. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
7. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
8. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
9. Proteonomix Announces a Private Placement of $3.8 Million
10. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
11. ARUP Laboratories Announces Creation of Business Innovations Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):